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Overline: Infectious disease 
One Sentence Summary: This study identifies oral, highly efficacious anti-wolbachial 
compounds to cure filarial infections. 
Abstract:  
Parasitic filarial nematodes cause debilitating infections in people in resource-limited 
countries. A clinically validated approach to eliminate worms uses a 4–6 week course of 
doxycycline that targets Wolbachia, a bacterial endosymbiont required for worm viability and 
reproduction. However, the prolonged length of therapy and contraindication in children and 
pregnant women have slowed adoption of this treatment. Here we describe discovery and 
optimization of quinazolines CBR417 and CBR490 that with a single dose achieve > 99% 
elimination of Wolbachia in the in vivo Litomosoides sigmodontis filarial infection model. The 
efficacious quinazoline series was identified by pairing a primary cell-based high content 
imaging screen with an orthogonal ex vivo validation assay to rapidly quantify Wolbachia 
elimination in Brugia pahangi filarial ovaries. We screened 300,368 small molecules in the 
primary assay and identified 288 potent and selective hits. Of 134 primary hits tested, only 
23.9% were active in the worm-based validation assay, eight of which contained a quinazoline 
heterocycle core. Medicinal chemistry optimization generated quinazolines with excellent 
pharmacokinetic profiles in mice. Potent anti-wolbachial activity was confirmed in L. 
sigmodontis, B. malayi, and Onchocerca ochengi in vivo preclinical models of filarial disease, 
and in vitro selectivity against Loa loa (a safety concern in endemic areas). The favorable 
efficacy and in vitro safety profiles of CBR490 and CBR417 further support these as clinical 
candidates for treatment of filarial infections. 
 
Introduction 
  
Parasitic filarial nematodes, including ones that cause lymphatic filariasis and 
onchocerciasis (also known as river blindness), were estimated in 2013 to infect 43.8 million and 
17 million people worldwide, respectively (1) with over a billion at risk of infection (2). Neither 
lymphatic filariasis nor onchocerciasis are commonly lethal; however, they are a recognized 
source of significant morbidity and suffering (3). In addition to acute symptoms, these long-term 
infections often result in disfigurement, social discrimination, and contribute to increased 
poverty of the afflicted individuals and their families. Both lymphatic filariasis and 
onchocerciasis are caused by long-lived filarial nematodes (roundworms) transmitted by blood-
feeding insect vectors. Onchocerciasis is caused exclusively by Onchocerca volvulus and 
lymphatic filariasis is caused mainly by Wuchereria bancrofti, and by the closely related Brugia 
species (B. malayi and B. timori). While the adults (macrofilariae) persist within human hosts for 
up to 15 years, they release thousands of microfilariae each day that are either the main cause or 
contribute to symptoms of disease and are also the developmental stage responsible for 
transmission back to the insect vector. 
There is no short course cure for these infections and current control treatments have 
been centered on mass drug administration (MDA) campaigns to interrupt transmission and to 
alleviate symptoms for the duration of the reproductive life-span of adult female parasites, 
variably estimated at 5–8 years (4). The recommended treatment for onchocerciasis is the drug 
ivermectin (Mectizan), administered at least once yearly to all at risk of infection. Ivermectin 
works by killing microfilariae and temporarily sterilizing, but not killing, adult worms. Current 
recommended treatment for lymphatic filariasis varies by geography: albendazole together with 
ivermectin in Africa where onchocerciasis is co-endemic with lymphatic filariasis, and 
albendazole with diethylcarbamazine in the rest of the world. These treatments likewise lead to 
the death of microfilariae, not the adult parasites, and these drug regimens must be maintained 
for at least five years. Although MDA of ivermectin for onchocerciasis has been ongoing for 
over 25 years (5), there are concerns over development of drug resistance (6), which has already 
been reported in veterinary medicine (7, 8), the extensive MDA coverage that must be achieved 
to meet elimination targets (9, 10), and with overall compliance of at-risk populations (11, 12). 
Additionally, treatments with diethylcarbamazine or ivermectin are contraindicated in patients 
with a high load of microfilariae of the African eye worm Loa loa, (>30,000 – 50,000 
microfilariae/mL of blood) due to severe adverse events (13). Lower  densities of microfilariae 
  
can also cause other, non-neurological adverse events, and overall concern over the potential for 
L. loa-associated side effects can reduce adherence to MDA campaigns (12). 
An attractive and clinically-validated strategy for developing a treatment to selectively 
kill adult worms is targeting the bacterial endosymbiont of onchocerciasis and lymphatic 
filariasis -causing worms, Wolbachia, which is absent from L. loa nematodes. Wolbachia are 
gram-negative obligate intracellular bacteria that are widely distributed among a variety of 
arthropods, where they are considered to be reproductive parasites, known for induction of 
parthenogenesis, feminization and male killing (14). In filarial nematodes, Wolbachia are 
essential endosymbionts, needed by adult worms for both reproduction and viability. Early 
experiments have shown that tetracycline treatment could prevent experimental infections of 
rodents with Brugia (15) and L. sigmodontis but not with the Wolbachia free species 
Acanthocheilonema viteae (16). The finding that Wolbachia is widely distributed among filarial 
nematodes (17), stimulated great interest in antibiotic anti-filarial therapy (18). Subsequently, it 
has been shown in humans that treatment with doxycycline over a period of four to six weeks to 
eliminate Wolbachia from adult worms is sterilizing and eventually macrofilaricidal, with life 
span of Wolbachia-depleted worms reduced by 70–80% (from ~10 years to 2–3 years) (19-22). 
An added benefit of this approach is potential reduction of inflammation, as adverse 
inflammatory reactions to anthelmintic treatment have been associated with Wolbachia released 
in patient plasma (23, 24). However, doxycycline is contraindicated for treatment of pregnant 
women and children under eight years of age. The prolonged length of treatment also represents 
potential challenges with compliance and contributes to cost of therapy, highlighting the need for 
faster, safer, and more effective therapies. Here we describe the identification of quinazolines 
CBR417 and CBR490 that are able to achieve very rapid clearance of Wolbachia from filarial 
nematodes in in vivo preclinical models of disease, and which offer the potential for 
development of a short-course cure to treat filarial worm infections. 
  
Results  
Primary high-throughput phenotypic screen identifies compounds with specific anti-wolbachial 
activity 
  
As no nematode cell lines have been established to date, tto rapidly identify compounds 
with anti-wolbachial activity we adapted and miniaturized an in vitro high-content imaging 
assay, which relied on Drosophila melanogaster cells naturally infected with wMel strain of 
Wolbachia (25). In the adapted assay, we used the LDW1 cell line (26) and two fluorescence in 
situ hybridization (FISH) probes specific to Wolbachia 16S rRNA to unambiguously stain 
Wolbachia and measure bacterial load inside host cells (Fig. 1A-C). Wolbachia are sensitive to 
tetracycline and rifamycin antibiotics (27, 28) and these controls demonstrated specific anti-
wolbachial activity in the assay, with doxycycline’s half maximal inhibitory concentration IC50 = 
279 nM and rifampicin IC50 = 5 nM (fig. 1D). Optimized assay conditions yielded a robust assay 
with Z’ factors > 0.5 (table S1). Further miniaturization to 1536-well format did not reduce assay 
quality (fig. 1C and table 1). Using this optimized assay, we screened ~300,368 small molecules 
from established libraries, including ReFRAME (29), for anti-wolbachial activity (table S1), with 
an overall hit rate of 0.70%. Reconfirmed hits were tested against Wolbachia in dose response 
and for cytotoxicity in the mammalian HEK293T and HepG2 cell lines (table S1). Overall, we 
identified and reconfirmed 299 potent (IC50 < 1 M) and selective (half maximal cytotoxic 
concentration (CC50):IC50 > 10) anti-wolbachial compounds (fig. 1D-G, H, table S1).  
We identified a number of known drugs and bioactive molecules among our potent and 
selective hits including antibiotics, signal transduction modulators, antineoplastics, antifungals, 
and antivirals (fig. 2, fig. S1, table S2).Antibiotics made up the largest category (46%) of the 
identified known drugs, and included tetracyclines, rifamycins, peptide deformylase inhibitors, 
pleuromutilins, fluoroquinolones, and aminocoumarins. Many of these displayed exquisite 
potencies against Wolbachia in vitro (e.g., coumermycin IC50 = 1.5 nM). Among the anti-
wolbachial antibiotic hits we also identified macrolide antibiotics tylosin and its derivative 
tylvalosin, with wMel IC50s of 720 nM and 350 nM, respectively. However, poor bioavailability, 
previously identified toxicity liabilities, challenging and costly synthesis, and most importantly 
lack of retained activity against filarial Wolbachia made these unattractive for repurposing or 
further development. 
We also identified a number of novel compounds among the hits. To determine if these 
anti-wolbachial hits were Wolbachia-specific and/or possessed antibiotic activity we screened 
them against a panel of extracellular bacteria. As expected, antibiotics and known drugs showed 
  
activity against many bacterial species, but very few novel small molecules inhibited microbial 
growth, even at the highest concentration tested of 20 M (fig. 2, table S3). This suggests that 
the novel chemical scaffolds identified in our screen had Wolbachia-specific activity or acted on 
a host cell process required for Wolbachia’s intracellular survival. Likewise, the optimized 
quinazoline leads CBR417 and CBR490 did not generally inhibit extracellular bacterial growth 
(table S4).  
 
A worm-based ex vivo assay rapidly identifies hits with anti-filarial Wolbachia activity 
Our primary cell-based assay identified compounds with activity against wMel, a strain 
of Wolbachia that infects D. melanogaster. Validation of anti-wolbachial compound activity 
against filarial Wolbachia commonly requires in vivo models, which is not amenable to rapid 
compound optimization cycles and has impeded drug discovery efforts. To overcome this 
limitation, we developed an orthogonal ex vivo validation assay that would allow us to prioritize 
hits in a native context against filarial Wolbachia (fig. 3, fig. 4A, fig. S2,). Based on previous 
studies (25), we selected quantification of filarial Wolbachia stained via 16S rRNA FISH near a 
convenient landmark for quantification, the ovary distal tip cell (DTC), of B. pahangi to validate 
our primary screen hits. The Wolbachia distribution in the ovaries is predictable and consistent 
compared to the variable distribution in hypodermal chords, with highest concentrations near the 
DTC (fig. 3A-F, fig. S2A, B, (30)), This population appears more refractive to compound 
treatment in the three day ex vivo assay compared to the population found in the hypodermis 
(fig. 3G, H), as has also been observed in Onchocerca ochengi worms in vivo (31). Moreover, 
the reproductive tract is a relevant site for anti-wolbachial drug action, and clearance in germ line 
stem cells is likely critical to prevent recrudescence of the bacteria following cessation of 
treatment. 
Doxycycline treatment of up to 9 M was insufficient to completely clear wBp from B. 
pahangi ovaries in three days, but 1 M and 3 M treatments eliminated approximately 75% of 
Wolbachia, with an estimated half maximal effective concentration (EC50) of 441 ± 64 nM (fig. 
4B–D). A similar result was observed with wBm strain of Wolbachia in B. malayi nematodes, 
where a 1 M doxycycline treatment eliminated 72.5% of Wolbachia (fig. S3). Benchmarking on 
this doxycycline activity, we established a validation threshold for our candidate anti-wolbachial 
  
compounds of ≥ 75% wBp elimination from the distal ovary at a compound concentration of 1 
M (fig. 4B).  
The ex vivo validation assay could be performed in eleven days, considerably reducing 
optimization cycle times versus the three month long in vivo validation assays, but was labor 
intensive, relying on nematode dissection and confocal imaging. Thus, based on activity and 
structural similarity clustering, we chose to test 137 out of our 299 primary hits (i.e., the most 
potent of any closely related analogs) (fig. 4E). Of these, 32 showed a ≥ 75% wBp elimination at 
1 M, for a validation rate of 23.4% (table S1, table S5). The percent elimination of wBp in 
worm ovaries was not generally correlated to compound potency observed in the primary D. 
melanogaster cell-based assay (R2 = 0.00048) (fig. 4F). Motility of worms was not affected by 
majority of compounds assayed, with the exception of methylene blue (table S2). Structure 
analysis of novel molecules demonstrated an enrichment of a quinazoline scaffold among 
validated compounds: out of eleven quinazolines tested in the secondary assay, eight 
quinazolines showed activity superior to doxycycline (fig. 4F). Members of this series displayed 
in vitro activity that correlated more with their activity in the ex vivo validation assay (R2 = 
0.3658) compared to all validated compounds (R2 = 0.0023) (fig. 4G). As quinazoline 
heterocycles are present in many of biologically active compounds including antibacterials (32, 
33), we focused on this series to improve their physiochemical properties and metabolic stability, 
and their activity against filarial Wolbachia. 
 
Quinazoline series demonstrates potent anti-filarial Wolbachia activity ex vivo and drug-like 
properties 
We carried out a medicinal chemistry campaign to optimize the potency, safety, and 
physiochemical and pharmacokinetic properties of the quinazoline series, starting with the screen 
hit CBR008. This involved iterative profiling of analogues in the in vitro cell-based and ex vivo 
worm-based assays to determine their anti-wolbachial activity. Compounds with ≥ 90% wBp 
elimination at 1 μM in the worm-based assay underwent absorption, distribution, metabolism, 
and excretion (ADME) profiling to assess cytochrome P450 (CYP) and human ether-a-go-go 
related gene (hERG) inhibition (to understand potential drug-drug interaction and cardiotoxicity 
liabilities of the compounds, respectively), metabolism in human and mouse liver microsomes, 
  
permeability in Caco-2 cells, kinetic solubility and plasma protein binding. Analogues with 
favorable properties (CBR422, CBR625, CBR715, CBR417, CBR490) were advanced for 
pharmacokinetic studies in mice to determine if their profiles were suitable for once-a-day (QD) 
or twice-a-day (BID) dosing in the in vivo preclinical models of infection (e.g. when dosed 
orally in mice at ≤ 50 mg/kg maintained plasma exposure over their wBp EC90s for at least 8 
hours (h)). As for doxycycline, the quinazoline series compounds had comparable anti-
wolbachial activity in B. pahangi and B. malayi worms in the ex vivo assay (determined for 
CBR422 and CBR625; fig. S3). 
Briefly, we found that replacing the amide with an oxadiazole isostere or methylpyridine 
at the C2 position of the quinazoline core and the trifluoromethyl with a pentafluorosulfanyl 
group improved the in vitro and ex vivo potencies, while increasing metabolic stability and 
pharmacokinetic properties of the compounds. This effort led to the initial lead CBR422, and the 
advanced (CBR625, CBR715) and optimized (CBR417, CBR490) quinazolines that had 
excellent potency, selectivity and ADME properties (table 1, table S6). Specifically, compared to 
screen hit CBR008 these analogues demonstrated improved in vitro and ex vivo potencies (wMel 
IC50 ≤ 33 nM; wBp EC50 ≤ 356 nM), an acceptable selectivity index, were orally bioavailable in 
mice, and had excellent pharmacokinetic properties with a prolonged blood plasma exposure 
time over EC90 when dosed at ≤ 50 mg/kg (> 12 h to > 24 h) (table S7). The identified CYP and 
hERG liabilities of the series (CYP 1A2 IC50 inhibition of 0.33 μM for initial lead CBR422 and 
hERG inhibition IC50 of 5 μM for CBR625) were markedly reduced in CBR417 (CYP inhibition 
≥ 30 μM for all isoforms, hERG IC50 = 19.5 μM) and partially addressed in CBR490 (CYP 1A2 
inhibition IC50 = 6.4 μM, hERG inhibition IC50 of 7 μM), while low kinetic solubility and high 
protein binding continued to be a feature of the analogs. Importantly, the advanced and 
optimized quinazolines were selective against L. loa microfilariae (that do not contain 
Wolbachia) in an in vitro motility assay, with IC50s of > 100 μM for CBR715, 87 μM for 
CBR417, and 64 μM for CBR490 versus the 11.3 μM IC50 of ivermectin (table 1).  
 
Optimized quinazoline series demonstrates in vivo efficacy with shortened duration of treatment 
in preclinical model of filarial infection 
  
A gold-standard in vivo preclinical model for assessing activity of anti-filarial 
compounds within a reasonable period of time utilizes mice infected with a filarial parasite of 
rodents, Litomosoides sigmodontis (fig. 6A) (16, 34). As L. sigmodontis are hosts to the 
Wolbachia endosymbiont, this is also an excellent preclinical model to assess anti-wolbachial 
compound action, which is done using quantitative PCR (qPCR) to determine the Wolbachia ftsZ 
gene to the L. sigmodontis actin gene ratio in female adult worms recovered from mice at the end 
of the experiment (4–6 weeks post treatment start; 65–77 days post infection). A series of studies 
in this model demonstrated that quinazoline potency in the ex vivo worm-based assay together 
with the ability of the compounds to achieve good exposure following oral dosing were essential 
for achieving efficacy. For example, an early analog CBR063 with good ex vivo potency (IC50 = 
89 nM; EC50 = 97 nM) failed to achieve Wolbachia clearance in vivo (fig. 6B), likely due to a 
comparably inferior pharmacokinetic profile (Cmax = 119 ± 38.3 ng/mL) (table S7). However, 
quinazoline analogues CBR422, CBR625, CBR715, CBR417, and CBR490 with excellent ex 
vivo potency and pharmacokinetic profiles, all proved efficacious in vivo with <14 day ≤ 60 
mg/kg BID dosing regimens (> 99% median Wolbachia clearance) and were significantly (P-
value < 0.05 to < 0.0001) superior to the 14-day 40 mg/kg BID doxycycline control ran in 
parallel (fig. 6B, fig. S5, table 2). 
Ability to achieve efficacy in preclinical models with a shortened duration of treatment (≤ 
7 days) is a desired profile because a reduced dosing schedule for an anti-wolbachial medication 
has the potential to facilitate treatment and improve compliance. Therefore, we explored 
shortened treatment regimens for the efficacious quinazoline analogs. Efficacy (99.80% 
Wolbachia elimination) was achieved with 60 mg/kg CBR625 BID 7-day dosing, and near-target 
efficacy (98.95% elimination) with 60 mg/kg QD dosing (fig. S5A, table 2). Likewise, an oral 7- 
and 12-day treatment of CBR715 at 50 mg/kg BID eliminated 98.86% and 99.80% of 
Wolbachia, respectively (fig. 6B, table 2). Sparse PK sampling during in vivo studies confirmed 
relative exposures of the tested quinazolines (fig. S4). Furthermore, an oral 4-day treatment at 60 
mg/kg QD with the optimized quinazolines eliminated 99.80% (CBR490) and 99.96% (CBR417) 
of Wolbachia in L. sigmodontis adult female worms, significantly superior (P-value = 0.0013 for 
CBR490 and P-value < 0.0001 for CBR417) to the 14-day doxycycline control ran in parallel 
(95.21% elimination) (fig. 6B, table 2).  
  
Due to the demonstrated potency and favorable exposures of optimized quinazolines 
CBR417 and CBR490 (time over EC90 of 72 h for a single 100 mg/kg PO dose; table S7)), we 
investigated whether an even more drastically abbreviated efficacious dosing regimen with these 
compounds were attainable. Both CBR417 and CBR490 were dosed at 100 mg/kg once per week 
over a two-week period (2 doses total) in the mouse/L. sigmodontis model and a 200 mg/kg 
single-dose was also evaluated. All treatment regimens eliminated > 99% of Wolbachia in L. 
sigmodontis adult female worms, significantly superior (P-value < 0.01) to the 14-day 
doxycycline control ran in parallel (95.21% elimination) (fig. 6B, table 2). Examination of in 
vivo efficacy in response to diverse dosing regimens showed that the dose of CBR490 was 
equally correlated to in vivo efficacy (R2 = 0.7263) as was total dose (R2 = 0.713) (fig. S6). Too 
few data points were available for CBR417 to make a conclusive analysis. 
 
CBR417 and CBR490 demonstrate favorable safety profiles in preclinical studies 
CBR417 and CBR490 safety profiles were more extensively assessed (table 3). Both 
compounds were well tolerated in mouse in vivo efficacy studies, even when administered at 
high doses 200 mg/kg (single dose) or for prolonged periods of time (CBR490 60 mg/kg daily 
total dose for 11 days). Neither compound showed intrinsic mutagenic potential based on 
negative results in mini-Ames, either in the absence or presence of rat liver S9 mix for metabolic 
activation. Micronucleus assays also did not reveal inherent genotoxicity potential. The CBR417 
oxadiazole did not strongly inhibit hERG or CYP enzymes (the latter assessed for potential drug-
drug interactions) and neither compound caused human PXR activation (a hallmark of CYP3A4 
induction). A prospective cardiovascular liability due to hERG inhibition was identified for 
CBR490 in preliminary profiling assays (IC50 = 7.07 M); however, a cardiac safety panel 
revealed no significant hits for either compound (table S8). To explore other potential off-target 
effects that could lead to in vivo toxicity, the Eurofins Cerep-Panlabs safety screen against 44 
selected targets was carried out and identified twelve targets significantly inhibited (> 50%) by 
CBR490 and only three inhibited by CBR417 (table S9). In summary, these findings demonstrate 
the favorable safety profiles of CBR417 and CBR490 quinazolines. 
 
  
Advanced quinazoline lead eliminates Wolbachia in B. malayi and Onchocerca adult worms in 
vivo  
Due to the demonstrated efficacy of optimized quinazoline analogues against Wolbachia 
in L. sigmodontis, we assayed one of these advanced leads (CBR715) for efficacy in preclinical 
murine models of B. malayi and Onchocerca adult worm infections. Retention of compound 
activity in the Onchocerca model was of particular concern, as both the Wolbachia 
endosymbionts and the Onchocerca hosts are more distantly related from the above 
host/endosymbiont models: Wolbachia of Onchocerca species belong to Supergroup C while 
Wolbachia of the more closely related L. sigmodontis and Brugia spp. belong to Supergroup D 
(35-37).The only available in vivo model of Onchocerca adult worms utilizes the bovine parasite 
O. ochengi (38), which is a sister species and the closest relative of the human river blindness 
parasite, O. volvulus (39). 
 The SCID mouse B. malayi and O. ochengi models were previously described, and like 
the mouse/L. sigmodontis efficacy model, rely on qPCR for quantification of filarial Wolbachia 
(38). In the B. malayi in vivo model (fig. 7A), treatments with CBR715 (7- and 14-day dosing 
schedules at 50 mg/kg BID) eliminated > 99% Wolbachia in B. malayi adult females, with the 
14-day CBR715 treatment eliminating significantly more Wolbachia (P-value = 0.0464) 
compared to the 42-day doxycycline control (fig. 7B). Doxycycline (42-day) and both CBR715 
treatments eliminated all circulating microfilariae (fig. 7C) and although a general trend of 
reduced adult worm burden was observed, these differences were not statistically significant (P-
value > 0.05) (fig. 7D). Likewise, in the O. ochengi in vivo model (fig. 7E), 7- and 14-day 
treatments with CBR715 eliminated > 99% Wolbachia in O. ochengi adult males, on par with the 
28-day doxycycline treatment control (fig. 7F), and no difference in percent recovery of 
implanted males was observed (fig. 7G). These data confirm the broad spectrum of activity of 
the optimized anti-wolbachial quinazoline series, and the continued superior performance of this 
series compared to doxycycline in in vivo preclinical rodent models of diverse filarial infections. 
 
 
Discussion  
  
Here we describe an accelerated drug discovery platform for the identification of anti-
wolbachial compounds and translation of these to efficacious leads in in vivo models of filarial 
infection. Previous screening efforts using high-throughput insect cell-based assays have 
identified anti-wolbachial compounds active in vitro, yet translation of these hits to in vivo 
models and the clinic has been challenging for a number of reasons. First, Wolbachia are 
obligate intracellular bacteria, and may only be propagated within appropriate host cells. As no 
nematode cell lines have been developed, for high throughput screening drug discovery 
researchers have relied on insect cell lines infected with Wolbachia strains that are specific to 
these hosts (25, 28, 40-42). Fortuitously, there are substantial similarities in the genetics and cell 
biology of the Wolbachia species that warrant using the infected insect cell lines as a primary 
screen and a high-throughput proxy for filarial Wolbachia-based assays. However, there are also 
considerable differences between Wolbachia strains, demonstrated not only by host range, but 
also by their genomes. For example, Foster et al reported a greater reduction of B. malayi 
Wolbachia wBm genome (in total size and predicted gene number) compared to D. melanogaster 
Wolbachia wMel (43). Thus, compounds identified in whole cell screens against insect 
Wolbachia may hit targets that are sufficiently divergent or even absent in filarial Wolbachia. 
Similarly, compounds that target a host cell factor to reduce Wolbachia load may be absent in 
filarial nematodes. Finally, filarial nematodes may shelter Wolbachia from compound action 
through limited permeability, compound metabolism, and/or excretion.  
To address these limitations, following up on initial studies (25) we developed an 
orthogonal assay in filarial nematodes that allowed us to rapidly assess anti-filarial Wolbachia 
activity of our primary screen hits. We utilized B. pahangi, a filarial parasite of cats but which 
can also infect humans (44), because these worms are closely related to B. malayi (45), but can 
be maintained in an animal host (jirds) in larger quantities, and therefore are more readily 
available. We focused our evaluation of Wolbachia load within worm ovaries for a number of 
reasons, including because this population appeared less sensitive to compound treatment than 
Wolbachia in the hypodermal chords of the animals, providing a more rigorous and pertinent 
read out of anti-wolbachial compound action. Interestingly, a similar differential susceptibility to 
compound action in the hypodermis versus the ovaries has been previously observed in vivo in 
O. ochengi adult worms following antibiotic treatments in cattle (31). The difficulty in 
eliminating different clades of Wolbachia from ovaries of different species of worms (Wolbachia 
  
supergroup D in Brugia spp. reported here and supergroup C in Onchocerca spp.) further 
supports the relevance of this tissue for assessment of anti-wolbachial compound efficacy. We 
utilized Wolbachia 16S rRNA FISH to detect the bacteria in both the cell-based high throughput 
assay and the ex vivo worm-based assay. In addition to its inherent specificity, rRNA provides a 
more sensitive viability metric, as it is less stable than DNA, allowing us to observe Wolbachia 
elimination in worm ovaries after only a relatively short three-day treatment ex vivo. While true 
markers of viability can be challenging to utilize in high-throughput screens, this approach gave 
us confidence in our ability to select fast-acting, anti-filarial Wolbachia compounds. 
In our primary insect cell-based screen, we identified known drugs with potent and 
selective anti-wolbachial activity. Among these were antineoplastics and signal transduction 
modulators, which potentially exert their activity by affecting host cell processes exploited or 
required by this obligate intracellular bacterium. For example Wolbachia has been found to alter 
lipid metabolism of mosquitoes (46), and insulin signaling and the TOR complex 1 pathway 
have been implicated in controlling Wolbachia titers in D. melanogaster (47, 48). Accordingly, 
in our screen we identified mTOR inhibitors and drugs affecting cellular metabolism (e.g., drugs 
for diabetes and liver X receptor agonists). We also identified many antibiotics with anti-
wolbachial activity, including ones belonging to antibiotic classes that have been previously 
identified in similar insect cell-based screens and assays (tetracyclines, rifamycins, 
pleuromutilins, fluoroquinolones, and macrolides (ABBV-4083, an orally available derivative of 
the macrolide antibiotic tylosin, is currently being developed as an anti-wolbachial therapy)) (27, 
28, 41, 49, 50), and others that to our knowledge have not been previously reported 
(aminocoumarins and peptide deformylase inhibitors). Notably, we found that most of these 
known drugs and antibiotics did not efficiently eliminate Wolbachia from B. pahangi ovaries in 
our ex vivo validation assay, regardless of their impressive potency in vitro. Therefore, while we 
relied on the high-throughput assay to identify potential anti-wolbachials, developing and 
utilizing an orthogonal assay that evaluated compound efficacy against Wolbachia in parasitic 
worms allowed us to prioritize molecules with rapid anti-filarial Wolbachia activity for further 
medicinal chemistry optimization. 
The desired profile for an anti-wolbachial macrofilaricide compound is the ability to 
cause > 99% depletion of Wolbachia in adult worms within 7 days of dosing in all three 
preclinical models of filarial disease (L. sigmodontis, B. malayi and O. ochengi). The oxadiazole 
  
and methylpyridine leads (CBR625, CBR417 and CBR715, CBR490) proved efficacious in vivo, 
causing a > 99% Wolbachia elimination in adult L. sigmodontis worms within the mandated 
dosing schedule of ≤ 7 days. Additionally, the advanced methylpyridine lead CBR715 
recapitulated this in vivo efficacy against Wolbachia in human parasite B. malayi and a close 
surrogate of O. volvulus (O. ochengi), demonstrating real promise in translation of the 
quinazoline series to a cure for human filarial infections. Our optimization strategy ultimately led 
to synthesis of leads CBR490 and CBR417 that with just a single-dose were efficacious in vivo 
at eliminating > 99% of Wolbachia from adult L. sigmodontis female worms. Abbreviated dosing 
schedules have a real advantage in treating infections in resource limited countries and 
elsewhere, as compliance and point of care distribution is greatly facilitated. Finally, both 
CBR417 and CBR490 demonstrated safety in initial in vivo and in vitro preclinical profiling and 
did not show strong activity in vitro against L. loa microfilariae (IC50 = 87 μM and 64 μM, 
respectively) compared to the ivermectin control (IC50 = 11.3 μM), suggesting that they would be 
appropriate for administration to patients in L. loa endemic regions following further safety 
assessments against L. loa microfilariae in vivo. 
Despite the promise of these results, we note limitations and outstanding questions that 
need to be addressed before clinical translation of this work. It should be noted that due to the 
length of time (years) needed for adult worm death following Wolbachia elimination, reduction 
in worm numbers in the murine assays is not anticipated and was not observed. However, the 
more immediate phenotype of worm sterilization was observed in the B. malayi murine model. 
Currently we also have no evidence that the observed Wolbachia elimination is sustained beyond 
four to five weeks following treatment, and studies using in vivo jird models that can 
accommodate patent filarial infections for at least six months (51) are necessary to determine the 
lowest efficacious dose of quinazolines that prevent Wolbachia recrudescence. Lastly, treatment 
of the large, long-lived female worms belonging to the Onchocerca spp. represents the ultimate 
challenge, with females containing 20x more Wolbachia than males (52). Therefore, further 
assessment of quinazoline efficacy in models that support Onchocerca female worms in vivo 
(such as the bovine model of infection) will likewise be required to determine efficacious dosing 
regimens.  
  
Recently, chemical optimization of the thienopyrimidine series identified in high-
throughput screening led to the generation of AWZ1066, a compound with a quinazoline 
scaffold and increased efficacy against both insect and filarial Wolbachia (53). However, 
quinazoline heterocycles are present in many biologically active compounds and whether 
CBR417, CBR490 and AWZ1066 share the same mechanism of action is uncertain. Genetic 
manipulation of Wolbachia has not been developed and its obligate intracellular lifestyle 
complicates target identification efforts, such as evolution of resistance and confirmation of 
putative targets via genetic means. Interestingly, AWZ1066 and many novel scaffolds identified 
in our primary screen, including the prototypical quinazoline CBR008, demonstrated very 
specific anti-bacterial spectrum of activity, which may indicate a Wolbachia- or Wolbachia host-
specific target. This also suggests that the quinazolines may be narrow spectrum antibiotics, a 
favorable profile for treating filarial nematode infections while reducing the effects of treatment 
on the microbiomes of treated individuals.  
In summary, our anti-wolbachial drug development platform enabled the path towards a 
short course oral therapy for elimination of Wolbachia-reliant filarial nematodes, including ones 
that cause lymphatic filariasis and onchocerciasis. Our work supports advancement of the 
oxadiazole and methylpyridine quinazoline subseries for additional preclinical safety assessment 
and indicates that quinazolines are a selective treatment for currently intractable filarial worm 
infections. 
 
Materials and Methods 
Study Design 
The objective of this study was to identify anti-filarial Wolbachia compounds with efficacy 
superior to that of doxycycline when administered with an abbreviated dosing schedule (≤ 7 
days). Wolbachia-infected Drosophila cell-based high-content imaging assay was used to screen 
for potent anti-wolbachial compounds, and putative hits were counter-screened in mammalian 
cells. Activity of potent and selective compounds was validated in an ex vivo whole worm assay 
observing filarial Wolbachia reduction in B. pahangi adult female ovaries, benchmarking on 
doxycycline activity. In vivo experiments were designed to compare Wolbachia reduction in L. 
sigmodontis, O. ochengi, or B. malayi adult worms between different treatment groups, a gold 
  
standard doxycycline and a vehicle control, in a randomized design with multiple arms and 
shared controls. The Wolbachia single gene ftsZ/worm actin ratios were compared to the vehicle 
and doxycycline treatment. Where applicable, sample size, selection, blinding schemes and 
replicates are provided in the figure legends and Materials and Methods. Primary data are 
reported in data file S1. 
Primary in vitro cell-based assay 
Wolbachia-infected LDW1 cells (26) were maintained in Shields and Sang M3 (SSM3) Insect 
Medium (Sigma) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) (qualified, 
One Shot Format, Gibco) at 25 °C, in flasks with unvented caps. Assay plates (Greiner, Part. No. 
789071 and 789091) were prepared by coating with 0.5 mg/mL (384-well plates) or 1 mg/mL 
(1536-well plates) solution of Concanavalin-A lectin (MP BIOMEDICALS). Compounds were 
acoustically transferred into coated plates using the Echo 555 Liquid Handler (Labcyte Inc.). 
Cells were trypsinized (TrypLE Express, Gibco), scraped, and seeded at 12,000 cells/well (384-
well plates) or 4,000 cells/well (1536-well plates) in SSM3 medium supplemented with 2% FBS. 
Plates were spun at 800 rpm for 3 min and incubated at 25 °C. Six days after seeding cells were 
fixed with 4% paraformaldehyde (PFA) for at least 10 min and washed with phosphate buffered 
saline, pH 7, 0.1% Tween 20 (PBS-T). FISH was used to stain Wolbachia and 3 M DAPI was 
used to stain DNA. The MultiFlo FX Multi-Mode Dispenser (Biotek) was used for 
Concanavalin-A coating, cell fixation and staining of 384-well plates and the “bottle valve” 
dispenser with an angled-head (Kalypsys Inc.) was used for processing of 1536-well plates. 
Plates were imaged using the CX5 Insight Cellomics high content imaging instrument with a 10 
objective (Thermo Fisher Scientific). Each well was analyzed using Compartmental Analysis in 
HCS Studio (Thermo Fisher Scientific) for cell number and Wolbachia content (see 
Supplementary Materials and Methods).  
Orthogonal ex vivo Brugia validation assay 
Adult B. pahangi and B. malayi females cultivated in and extracted from peritoneal cavities of 
jirds (Meriones unguiculatus) were obtained mainly from TRS Laboratories. B. pahangi were 
also provided by Dr. Brenda T. Beerntsen (University of Missouri), and the NIH/NIAID 
Filariasis Research Reagent Resource Center for distribution by BEI Resources, NIAID, NIH: 
  
Adult Female Brugia pahangi (Live), NR-48903. Following shipment, worms were immediately 
separated into 24-well plates, one animal per well, and allowed to recover for two days in high 
glucose RPMI 1640 Medium (ATCC modification) (Gibco) supplemented with 10% MEM 
(Gibco) and 10% heat-inactivated HyClone FBS (GE Healthcare Life Sciences). Media was 
changed daily and compounds tested at indicated concentrations (0.1% DMSO). Gross motility 
of worms was observed by eye during treatment and compared to DMSO controls. After three 
days of treatment animals were frozen at -80 °C, thawed, and fixed for 20 min with 3.2% PFA in 
PBS-T. Ovaries were dissected out, stained for Wolbachia using a modified FISH protocol, 
mounted on slides using Vectashield with DAPI mounting medium (Vector Laboratories Inc., H-
1200), and imaged using a confocal microscope (see Supplementary Materials and Methods). To 
reduce variability, worms originating from a single jird were used in each experiment. The 
experiments were carried out partially blinded, as with the exception of DMSO and doxycycline 
controls identity of tested compounds was masked during treatment, imaging, and analysis. 
Statistical analysis 
 
Percentage Wolbachia reduction in macrofilariae were normalized to median vehicle control 
values derived from the same experimental infection and screen. Where available, repeat 
experimental data were pooled following normalization. For analysis of Wolbachia depletion in 
in vivo experiments, where majority of grouped data failed the D’Agostino & Pearson normality 
test (P-value > 0.05), a non-parametric Kruskal-Wallis test with Dunn’s correction for multiple 
comparisons was used to determine significance, and medians with 95% confidence intervals are 
shown. Comparisons between vehicle and all treatment groups and doxycycline and all treatment 
groups were preselected. All statistics were computed using GraphPad Prism v6.0h.  
 
Supplementary Materials 
Supplementary Materials and Methods 
Fig. S1. Classes of known drugs and bioactive molecules identified as potent and selective anti-
wolbachial hits in the primary in vitro screen. 
Fig. S2. Wolbachia distribution in ovaries and the hypodermis of DMSO treated worms. 
  
Fig. S3. Wolbachia elimination from B. malayi worm ovaries ex vivo. 
Fig. S4. Sparse pharmacokinetic profiles of quinazoline anti-wolbachials during efficacy studies. 
Fig. S5. Wolbachia elimination following quinazoline treatment in the mouse/L. sigmodontis in 
vivo model of filarial infection. 
Fig. S6. CBR417 and CBR490 dose-response relationship based on Wolbachia elimination in 
mouse/L. sigmodontis efficacy studies. 
 
Table S1. Primary and validation screen statistics. 
Table S2. Anti-wolbachial activities of known drugs and bioactive molecules identified as potent 
and selective hits in the primary in vitro screen (powders and ReFRAME compounds). 
Table S3. Antibacterial activities of primary screen hits from Bioactive, Diversity I and Diversity 
II libraries. 
Table S4. Activity of optimized anti-wolbachial leads against a panel of gram-positive and gram-
negative bacteria. 
Table S5. Activities of screening hits validated ex vivo (all except ReFRAME compounds are 
powders). 
Table S6. ADMET properties of quinazoline anti-wolbachials. 
Table S7. Pharmacokinetic properties of anti-wolbachial quinazolines. 
Table S8. Cardiac Panel Study Results for CBR417 and CBR490. 
Table S9. Safety Pharmacology Profiling Study Results for CBR417 and CBR490.  
Data file S1. Primary data. 
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Figures and Tables: 
Fig. 1. A primary cell-based high-throughput phenotypic screen identifies compounds with 
potent and selective anti-wolbachial activity. A) Schematic of primary anti-wolbachial screen 
workflow. B) Representative images from DMSO- and doxycycline-treated wells. One field of 
view (covering nearly the entire surface of each well) and a zoomed in segment with or without 
analysis overlays are shown (outline of LDW1 cell nuclei in blue, perimeter of analysis area 
extending beyond the nucleus in purple, and the identified Wolbachia spots are demarcated with 
a transparent red mask). In the merged image Wolbachia 16S rRNA FISH signal is colored 
magenta and DNA signal (DAPI) is colored green. Raw and normalized values (see Materials 
and Methods) calculated from the images shown in (A) are listed. Scale bar = 100 m. C) Heat 
map images of analysis results from plates ran in triplicate. Normalized % activity values for 
Wolbachia signal and cell numbers are indicated according to the scale bar. DMSO-treated wells 
in column 45 and individual positive control-treated wells (blocks of wells with 12.5 μM 
doxycycline, 0.125 μM rifampicin, or 12.5 uM puromycin) in column 46. D) 11 point 1:3 dose 
response curves of known antibiotics with activity against Wolbachia, including puromycin cell 
toxicity positive control. E) LDW1 cell number dose response data. F) Mammalian HEK293T 
cytotoxicity dose response data. Puromycin CC50 is shown. G) Powder reconfirmation results for 
Bioactive and Diversity libraries and (H) the ReFRAME library, where the wMel IC50s of each 
compound are plotted against their mammalian cytotoxicity (HEK293T CC50s). Compounds are 
color-coded based on library origin. Hit potency and selectivity criteria (IC50 < 1 M, CC50:IC50 
> 10) are shown as solid lines and grayed out areas represent values which do not meet these 
thresholds. Dotted lines represent maximal concentrations tested in dose response studies (e.g. 
12.5 M in the anti-wolbachial primary assay).  
Fig. 2. Novel small molecules with anti-wolbachial activity possess a narrow anti-bacterial 
spectrum. Select powder stocks of compounds identified from Bioactive, Diversity I, and 
Diversity II libraries that displayed potent anti-wolbachial activity and were not significantly 
toxic to mammalian cells were tested against a panel of gram-positive and gram-negative 
bacteria. Bacterial viability inhibition following treatment with 5 M or 20 M of each 
compound was determined by optical density measurements. 
  
Fig. 3. Wolbachia populations in B. pahangi adult female worms demonstrate differential 
susceptibility to anti-wolbachial treatment. The effects of short anti-wolbachial ex vivo 
treatments on Wolbachia populations within adult female B. pahangi worms were evaluated. 
Worms were treated ex vivo for three days with doxycycline or anti-wolbachial series lead 
CBR422 and Wolbachia load was quantified using Wolbachia-specific 16S rRNA FISH and 
imaging (in distal ovaries) or qRT-PCR (in whole worms or tissues). DAPI (green) and 
Wolbachia-specific 16S rRNA FISH (white or magenta) staining in ovaries of DMSO (A, D), 1 
M doxycycline (B, E), and 0.33 M CBR422 (C, F) treated worms. A–C) Images of dissected 
and stained ovaries acquired using a 10x objective of a confocal microscope. Distal ovaries are 
indicated with boxes and arrowheads; oviducts and distal uteri are indicated with dashed lines 
and arrows. Scale bar = 100 m. D–F) Images of distal ovaries shown in A–C, acquired using a 
63x objective of a confocal microscope. DTC, distal tip cell. Scale bar = 10 m. Wolbachia 
elimination (%) determined using high content image analysis is indicated for each section. G) 
Wolbachia quantities in distal ovaries compared to those in whole worms following doxycycline 
(n = 3) or CBR422 (n = 2) treatment. H) Wolbachia quantities in distal ovaries compared to 
those in the entire reproductive tract or body wall tissues following doxycycline treatment (n = 
1). Values for each experiment were normalized to DMSO-treated controls and mean  stdev are 
shown. 
Fig. 4. An ex vivo worm-based validation assay rapidly identifies compounds with anti-
filarial Wolbachia activity. A) Schematic of secondary ex vivo validation screen workflow to 
assess Wolbachia elimination in B. pahangi adult worm ovaries. Two worms (yielding a 
maximum of four ovaries) were included in each treatment. B) Characterization of doxycycline 
activity against Wolbachia within B. pahangi ovaries treated ex vivo. Shaded green region 
indicates the selected validation threshold of > 75% Wolbachia elimination following 1 M 
treatment. Data from > 3 separate experiments are plotted as mean  stdev. C) Representative 
images from DMSO- and (D) 1 M doxycycline-treated ovaries stained with DAPI (green) and 
Wolbachia (magenta). Analysis overlays used to quantify Wolbachia-specific signal are 
represented as a semi-transparent red mask. DTC, the distal tip cell, is indicated with a dashed 
outline. Scale bar = 10 m. Boxes surround areas that are magnified 2.6x to the right of each 
image; Wolbachia-specific signal (arrow). E) Validation results for potent and selective primary 
  
screen hits, tested in the assay at 1 M. Results are grouped and colored by the library from 
which each hit originated. Control compounds tested at 1 M: DOX, doxycycline; MIN, 
minocycline; RIF, rifampicin. Data are represented as mean  stdev (1–4 ovaries per treatment). 
Gray area in the graph represents activities below the set validation threshold. F) wBp 
elimination in B. pahangi worm ovaries plotted against wMel IC50s obtained in the primary 
insect cell-based assay. Doxycyline, minocycline, and rifampicin controls are indicated and test 
compounds are colored by the library from which they originated. Data for quinazolines are 
indicated as donuts. Gray area in the graph represents activities below secondary assay’s 
validation threshold. G) wBp EC50s obtained for select compounds validated in the secondary 
worm assay plotted against wMel IC50s obtained in the primary insect cell-based assay. 
Compounds are labeled according to library origin. Quinazolines, are indicated as donuts and the 
structure of the most potent, CBR008, is shown. Coefficient of determination (R2) calculated for 
all compounds is shown in blue (with the associated regression line; dashed blue) and in green 
for just the quinazolines.Fig. 5. Optimized quinazoline anti-wolbachials demonstrate 
superior pharmacokinetic profiles. Mice were dosed orally with compounds at indicated 
amounts. Concentration of each compound in plasma was monitored for at least 24 h. For each 
compound, wBp EC90s established in the worm-based ex vivo assay are indicated by a red dashed 
line. Exposure profiles of A) the primary screen hit amide CBR008 and its more potent analog 
CBR063, B) the oxadiazole series lead CBR422, C) the advanced lead oxadiazole CBR625, D) 
the optimized series lead oxadiazole CBR417, E) the advanced lead methylpyridine CBR715, 
and F) the optimized series lead methylpyridine CBR490. CBR008 and CBR063 were 
formulated in polyethylene glycol 300/5% dextrose in water (3:1, v/v); all other compounds were 
formulated in 40% (2-Hydroxypropyl)--cyclodextrin. Mean ± stdev (n = 3 mice) are shown. 
Fig. 6. Quinazolines demonstrate anti-wolbachial efficacy in mouse model of L. sigmodontis 
filarial infection. A, B) Advanced anti-wolbachial compounds were assayed in an in vivo model 
of L. sigmodontis filarial infection where mice (n = 4–6/group) infected with adult L. 
sigmodontis filarial worms (infected by mites carrying L. sigmodontis infectious larvae) are 
dosed for up to 14 days with a compound of interest. B) Wolbachia load per worm was 
determined by the ratio of Wolbachia ftsZ gene to that of filarial actin. Vehicle control and a 14-
day 40 mg/kg BID doxycycline control were included in each independent experiment. Medians 
with 95% CI are shown and median % elimination is reported (nd, no significant difference; * P-
  
value < 0.05; ** P-value < 0.01; *** P-value < 0.001; **** P-value < 0.0001). DOX, 
doxycycline; mpk, mg/kg.  
Fig. 7. Quinazoline CBR715 demonstrates anti-wolbachial efficacy in mouse models of B. 
malayi and O. ochengi filarial infection. A) Efficacy of CBR715 against Wolbachia in B. 
malayi was assessed in a mouse model of infection where mice (n = 6/group) are inoculated with 
infectious L3 larvae of B. malayi. B) Wolbachia content in adult worms determined six weeks 
after the beginning of treatment is shown. Effect of CBR715 and doxycycline (DOX) control 
treatments on C) the number of mf circulating in the blood, and D) total B. malayi worm burden 
at the end of the in vivo experiments is shown. E) Advanced lead CBR715 efficacy against 
Wolbachia in O. ochengi was assessed in a mouse model of infection where mice (n = 6/group) 
are implanted with O. ochengi adult male worms. F) Wolbachia content in adult worms 
determined five weeks after the beginning of treatment. G) Effect of CBR715 and doxycycline 
(DOX) control treatments on total O. ochengi male worms recovered at the end of the in vivo 
experiments. To assess significance between treatment groups the non-parametric Kruskal-
Wallis test with Dunn’s multiple comparison test was used. Black lines indicate significant 
differences between vehicle control and treatment groups and blue lines indicate significant 
differences between DOX and treatment groups (nd, no significant difference; * P-value < 0.05; 
** P-value < 0.01; *** P-value < 0.001; **** P-value < 0.0001). 
  
  
 
  Screen Hit 
Failed 
Subseries 
Lead 
Successful 
Subseries 
Lead 
Advanced Leads Optimized Leads 
  CBR008 CBR063 CBR422 CBR625 CBR715 CBR417 CBR490 
Subseries amide amide oxadiazole oxadiazole methylpyridine oxadiazole methylpyridine 
    
     
MW 346.179 400.151 371.099 430.064 380.15 444.079 438.094 
in vitro HCI cell-based assay: anti-Wolbachia wMel in D. melanogaster LDW1 cells 
anti-Wolbachia wMel 
IC50 (nM) 
293 89 7 6 21 24 33 
anti-Wolbachia wMel 
IC90 (nM) 
735 200 43 52 182 1640 283 
ex vivo worm-based assay: anti-Wolbachia wBp in B. pahangi ovaries 
anti-Wolbachia wBp 
EC50 (nM) 
242 97 26 66 51 356 < 111 
anti-Wolbachia wBp 
EC90 (nM) 
799 221 189 346 396 777 < 111 
% Wolbachia wBp 
elimination at 1 M 
86.3% 98.0% 93.5% 95.5% 94.5% 88.0% 95.5% 
in vitro mammalian cytotoxicity assay and compound selectivity 
HEK293T CC50 (μM) 10.4 18.6 34.95 15.7 26.8 12.6 2.2 
HepG2 CC50 (μM) 21.2 30.0 > 40 11.3 13.7 9.7 1.6 
HEK293T CC50/IC50 35 209 5081 2735 1299 525 66 
 HepG2 CC50/IC50 72 336 > 5816 1968 663 294 49 
in vitro L. loa microfilaria selectivity 
L. loa microfilaria 
motility IC50 (μM) 
n/d n/d n/d n/d > 100 86.9 63.6 
(ivermectin control IC50 
= 11.3 μM) 
              
 
 Table 1. Structures and activities of quinazoline anti-wolbachials. 
  
  
Dose 
(mpk) 
Days of dosing CBR063 CBR422 CBR625 CBR715 CBR417 CBR490 
 1 2 3 4 5 6 7* 8 9 10 11 12 13 14       
B
ID
 d
o
s
in
g
 
100 •• •• •• •• •• ••                       99.88%     
60 •• •• •• •• •• •• ••                   99.80%       
60 •• •• •• •• •• •                           99.91% 
50 •• •• •• •• •• •• •• •• •• •• •• •• •• •• -68.85%           
50 •• •• •• •• •• •• •• •• •• •• •• ••           99.80%     
50 •• •• •• •• •• •• •• •• •• •• ••         99.59%         
50 •• •• •• •• •• •• ••                     98.86%     
30 •• •• •• •• •• •• •• •• •• •• •• •• •• ••     99.89%       
30 •• •• •• •• •• •• •• •• •• •• ••                 99.68% 
30 •• •• •• •• •• •• •• •• •               98.86%       
30 •• •• •• •• •• •• ••                   93.20% 57.75%     
10 •• •• •• •• •• •• ••                   66.43%       
Q
D
 d
o
s
in
g
 
60 • • • • • • •                   98.95% 48.59%   99.72% 
60 • • • • • •                         99.61%   
60 • • • •                             99.96% 99.88% 
30 • • • • • • •                   42.86%     99.94% 
30 • • • •                               80.73% 
10 • • • • • • •                   54.29%     55.14% 
w
e
e
k
ly
 200 •                                   99.92% 99.88% 
100 •             •                     99.83% 99.87%** 
                                            
* Desired dosing profile for a macrofilaricide: Oral dose, once daily, up to 7 days or single, intra-muscular injection.     
** Mean of two independent experiments                       
 
Table 2. Wolbachia elimination from female adult worms achieved following quinazoline 
treatment in the mouse/L. sigmodontis in vivo model of filarial infection. For ease of 
interpretation efficacy values are presented in table cells colored on a sliding scale with excellent 
efficacy (>99% to 98% elimination of Wolbachia) in green, medium levels of efficacy (95% to 
80% elimination) in yellow, and inferior levels in orange (70% to 40% elimination) and red 
(<30% elimination). 
  
  
  CBR417 CBR490 
  oxadiazole methylpyridine 
Molecular Weight (daltons) 444.079 438.094 
Solubility (pH 6.8) (μM) 1 1 
Melting Point (C) 149 – 153 250 – 253  
Lipohilicity (cLogP) 4.44 6.18 
Plasma Protein Binding 
> 99.9 % (human) 
> 99.9 % (mouse) 
98.08 % (human) 
> 99.9 % (mouse) 
Permeability Caco-2     
Papp A-B (10-6 cm/s) 2.08 0.14 
Papp B-A (10-6 cm/s) 1.79 0.26 
Metabolic stability (M / R / D / H) 
Extraction ratio (%) 52 / 20 / 30 / 41 86 / 35 / 39 / 63 
T1/2 (min) 56 / 145 / 145 / 88 10 / 85 / 100 / 35 
CLint (μL/min/mg) (Rat) 25 / 10 / 10 / 16 137 / 16 / 14 / 39 
hERG (cardiotoxicity) - manual patch clamp   
% inhibition at 5 μM 20.5 27.1 
IC50 (μM) 19.5 7.1 
Cardiac panel safety profilinga 
No significant 
inhibition 
No significant 
inhibition 
Mini-AMES (genotoxicity) negative negative 
Micronucleus induction (mutagenicity) negative negative 
Cytochrome P-450 isoform (IC50) (μM) 
Reversible 1A2 29.52 6.38 
Reversible 2C19 > 50 11.25 
Reversible 2C9 45.34 6.81 
Reversible 2D6 > 50 13.00 
Time-dependent inhibition 3A4 > 50 > 50 
CYP induction, PXR functional assay > 30 > 30 
Safety pharmacology profilingb 
(selected receptors, ion channels, 
transporters, kinases, etc.) 
4 with > 45% 
binding/inhibition 
14 with >45% 
binding/inhibition 
P-glycoprotein inhibition,  
MDCK-MDR1  IC50 (μM) 
6.5 1.49 
  
      
a Table S8     
b Table S9     
 
Table 3. In vitro ADME and safety profiling data for optimized leads CBR417 and CBR490. 
  
  
Bakowski et al. 2018 Supplementary Materials  
Supplementary Materials and Methods: 
Primary in vitro cell-based assay details 
Assay plates were coated with Concanavalin-A to facilitate cell adhesion. The Concanavalin-A 
solution was dispensed into wells, aspirated after a 10-min incubation, and plates were allowed 
to dry in a laminar flow hood for at least 2 h, then stored at 4 °C. 
For high content analysis, host cell nuclei were identified using DAPI signal and a generous 
perimeter (radius increased by 5 pixels) was demarcated around this region to define the cell 
area. Far red (16S rRNA FISH)-stained spots within all identified cells were selected based on 
their signal intensity above background using the box detection method and fixed thresholding. 
Analysis outputs included 1) the total number of LDW1 cells per well, and 2) the Wolbachia 
signal, quantified by the total fluorescence intensity of all 16S rRNA FISH-stained spots within 
all identified LDW1 cells (averaged per well). 
Compounds from five libraries, including one Bioactive (collection of known annotated 
compounds) and three Diversity libraries (collection of proprietary and commercial compounds 
with drug-like properties), and the newly-assembled Repurposing, Focused Rescue, and 
Accelerated Medchem (ReFRAME) (29) were screened at a single concentration of 2.5 M and 
primary hits showing significant reduction of Wolbachia signal (≥ 60 or ≥ 70%, as indicated) 
underwent initial triplicate reconfirmation in single point or were directly assayed in 8-point 
serial dilutions to generate dose response curve data (Table 1). Reconfirmed hits were tested 
against Wolbachia in 8-point dose response and for cytotoxicity in the mammalian HEK293T 
cell line. Mammalian cytotoxicity was used to down-select toxic hits, as insect cell toxicity was 
rare under the screening conditions.  
To verify activity and where available, powder stocks of potent (IC50 < 1 M) and selective 
(CC50:IC50 > 10) compounds from the Bioactive and Diversity libraries were re-tested in 11-
point dose response against Wolbachia and for cytotoxicity in mammalian HEK293T and HepG2 
cell lines, with a total of 313 powders tested. The known anti-wolbachials doxycycline and 
rifampicin were re-discovered in the Bioactive library as potent and selective but were omitted 
from powder reconfirmation. The ReFRAME library as tested was newly-assembled and in 
excellent condition (e.g. 54% of primary hits directly tested in 8-point dose response reconfirmed 
  
with an IC50 < 1 M) and therefore powders of ReFRAME hits were not re-tested in primary 
assays. Reconfirmed hits from the ReFRAME library have been deposited in the reframedb.org 
data portal.  
Fluorescence in situ hybridization (FISH) 
Two oligonucleotide probes labeled on 5’ ends with Quasar 670 (Biosearch Technologies) 
complementary to Wolbachia 16S rRNA were used for FISH labeling experiments. Probe W2 
[5’-CTTCTGTGAGTACCGTCATTATC-3’] has been previously described (54) and a new 
probe Wpan1 [5’-CCCCAGGCGGAATGTTTA-3’] was designed based on E. coli 16S rRNA 
accessibility data (55). Probes were tested in wMel-infected LDW1 and tetracycline-cured 
LDW1 cell line. Each probe is complimentary to the 16S rRNA sequences of both wMel and 
wBp strains and they were used simultaneously to improve detection. For the in vitro cell-based 
assay, fixed cells were incubated with FISH hybridization buffer over night at 37 °C (50% 
deionized formamide, 4 SSC, 10x Denhardts solution, 0.2 M DTT, 0.1% Tween 20, 0.5 M 
W2, and 0.5 M Wpan1). Cells were rinsed once and then washed at 42 °C for 1 h with 1 Wash 
Buffer (1SSC, 10 mM DTT, 0.1% Tween20), then rinsed and washed for an additional 1 h with 
0.5 Wash Buffer. For the ex vivo B. pahangi validation assay, dissected ovaries were stained as 
above, with the following additions to the FISH hybridization buffer to improve sensitivity: 
8.25% dextran sulfate and 0.5 M each unlabeled helper oligos W2H1 [5’-
TTCCTCACTAAAAGAGCTTT-3’](56), W2H2 [5’-CACGGAGTTAGCCAGGACT-3’](56), 
and newly-designed Wpan1H1 [5’-ACGCGTTAGCTGTAATAC-3’], Wpan1H2 [5’-
TAATCTTGCGACCGTAGT-3’]. 
Mammalian cytotoxicity counter screen 
HepG2 (ATCC) and HEK293T (ATCC) mammalian cell lines were maintained in Dulbecco's 
Modified Eagle Medium (DMEM, Gibco) with 10% heat-inactivated HyClone FBS (GE 
Healthcare Life Sciences), 100 IU penicillin, and 100 mg/mL streptomycin (Gibco) at 37°C with 
5% CO2 in a humidified tissue culture incubator. To assay mammalian toxicity of hit 
compounds, 750 HepG2 and 375 HEK293T cells/well were seeded in assay media (DMEM, 2 % 
FBS, 100 IU penicillin, and 100 mg/mL streptomycin) in 1536-well, white, tissue culture-treated, 
solid bottom plates (Corning, 9006BC) that contained acoustically transferred compounds in a 
  
three-fold serial dilution starting at 20 or 40 M. After a 72-h incubation, CellTiter-Glo 
Luminescent Cell Viability Assay (Promega) was used to quantify cell viability as per 
manufacturer instructions. Luminescence signal was read on the PHERAstar FSX plate reader 
(BMG Labtech).  
Confocal microscopy 
The Leica SP5 confocal microscope was used to image the central plane of ovaries using a 10 
air (HCX PL APO CS 10.0x0.40 DRY, Leica Microsystems) or 63 glycerol objective (HCX PL 
APO CS 63.0x1.30 GLYC 21°C, Leica Microsystems). Only ovaries where the distal tip cell was 
positively identified based on cell morphology were imaged and analyzed. For each experiment, 
parameters of the microscope such as light intensity, exposure time, camera gain, etc., were 
determined for the DMSO control sample and consistently applied to subsequently imaged 
specimens. Confocal images were imported and Wolbachia content of each ovary analyzed using 
Compartmental Analysis in HCS Studio (Thermo Fisher Scientific) as for the cell-based assay. 
Relative quantitative RT-PCR 
Adult B. pahangi females were treated as described for the secondary ex vivo assay. After three 
days of treatment animals were frozen at -80 °C. TRI Reagent RT (Molecular Research Center 
Inc.) was added directly to each frozen worm and plates were kept at -80 °C until processing. To 
disrupt animal tissues and bacteria the samples were thawed and processed with the Precellys 24 
homogenizer (Bertin Corp) (2  30 seconds at 6,500 rpm, 5 second rest between cycles, samples 
on ice for 5 minutes and disruption cycle repeated) using the VK05 Tough Micro-Organism 
Lysing Kit (0.5 mm glass beads in 2 mL tubes). GlycoBlue Coprecipitant (Ambion) was 
included (30 g/mL) for improved RNA recovery. RNA extraction was performed according to 
manufacturer directions. The qScript cDNA SuperMix was used for cDNA preparation from 250 
ng of RNA per sample and SsoAdvanced Universal SYBR Green Supermix was used for qRT-
PCR using the Applied Biosystems ViiA 7 Real-Time PCR System. Primers were designed using 
the Primer 3 software (57, 58). The target gene used to measure Wolbachia load was the wBp 
wsp gene, with primers designed based on the available partial wBp wsp cDNA sequence 
(AY095211.1). The putative B. pahangi splicing factor U2 auxiliary factor 65 kDa subunit 
(U2AF2) (BPAG_0001183401) gene was chosen as the reference gene for the qRT-PCR assay 
  
because its B. malayi orthologue (Bm1_09760) is similarly expressed across all filarial life cycle 
stages (59). Likewise, we found that the putative U2AF2 is similarly expressed in B. pahangi in 
control and drug-treated animals (Ct value % CV < 1.8 for each experiment) and is expressed at 
approximately the same Ct as the target wsp gene in control animals. Relative expression ratios 
of the target wsp and reference U2AF2 gene in control and treated samples were computed 
correcting for primer efficiency using the Pfaffl method (60).  
qRT-PCR Primers 
Primers U2_F2 [5’-AGATCGTGATCGACGGAAGT-3’] and U2_R2 [5’-
TTTCAGGTGTACGCTCCTTG-3’] are specific to B. pahangi BPAG_0001183401 (putative U2 
auxiliary factor 65 kDa subunit) and span the exon2-exon3 splice junction. 
Primers wsp_F1 [5’-TGGTGGTAGTGCATTTGGTT-3’] and wsp_R1 [5’-
TGGAGTAGGAGCTCGTGAAA-3’] are specific to Wolbachia wBp wsp (partial Wolbachia 
wBp surface protein cDNA, AY095211.1). 
Data analysis 
Primary in vitro screen and mammalian cytotoxicity counter screen data were uploaded to 
Genedata Screener, Version 13.0.1-Standard. Data was normalized to DMSO (neutral) and 
inhibitor control-treated wells (neutral controls minus inhibitors), with 12.5 M doxycycline 
(Sigma) and 125 nM rifampicin (Sigma) used as positive controls. For the mammalian 
cytotoxicity counter screen 40 M puromycin (Sigma) was used as the positive control. 
Replicate data were analyzed using median condensing. Dose response curves were fitted with 
the four parameter Hill Equation. For the orthogonal ex vivo assay, average Wolbachia spot total 
intensity per cell data for each ovary were normalized to averaged data obtained from DMSO 
treated ovaries in the same experiment to determine % Wolbachia elimination (100 ∙ (mean 
DMSO – sample)/mean DMSO). Dose response curves were fitted with the variable slope (four 
parameters) least squares fit using GraphPad Prism. Due to limited data points for each curve 
(most often three) and data normalization, constraints for bottom (=0) and top (=100) plateau 
parameters were set. Likewise, qRT-PCR data were normalized to averaged data obtained from 
DMSO controls in the same experiment to determine % Wolbachia elimination. 
Bacterial panel 
  
Bacterial inocula were grown at 37C in 384-well clear bottom plates in Mueller-Hinton II Broth 
(cation adjusted) in the presence of acoustically transferred compounds of interest, except for 
Mycobacterium tuberculosis which was cultured in Middlebrook 7H9 medium. After an 18-h 
incubation (5 days for M. tuberculosis), the absorbance of the cultures was determined in the 
Perkin Elmer EnVision microplate reader and % inhibition of growth relative to vehicle treated 
control (DMSO) was determined. Bacterial strains used were Bacillus subtilis (ATCC 23857), 
Enterococcus faecalis (ATCC 29212), Enterococcus faecium (ATCC 35667), Staphylococcus 
aureus (ATCC 43300), M. tuberculosis (H37Ra; ATCC 25177), Pseudomonas aeruginosa 
(ATCC 15692), Klebsiella pneumoniae (ATCC 700603), and Acinetobacter baumannii (ATCC 
17978). To evaluate the antibacterial activity of CBR417 and CBR490, bacteria were grown at 
37C in 1536-well white solid-bottom plates in Mueller-Hinton II Broth (cation adjusted) in the 
presence of acoustically transferred compounds in a three-fold serial dilution starting at 40 M. 
After a 24-h incubation, BacTiter-Glo Microbial Cell Viability Assay (Promega) was used to 
measure bacterial viability as per manufacturer instructions. 
Mouse/L. sigmodontis in vivo anti-wolbachial efficacy model of patent filarial infection 
To assess efficacy of drug candidates in the L. sigmodontis in vivo mouse model, female 
BALB/c wildtype mice (Janvier) were infected at 6-8 weeks via exposure to Ornithonyssus 
bacoti mites containing infective L. sigmodontis L3 larvae as previously described (61). The 
same batch of mites was used to infect all animals within one experiment to allow comparable 
infections. At 35/36 days post infection (dpi), a time point adult worms have developed in the 
thoracic cavity, mice were treated by oral gavage with the test compounds at indicated doses and 
regimens using 40% Cylclodextrin in water as vehicle and a dosing volume of 10 mL/kg. As 
positive control, mice received BID treatments with doxycycline-hyclate (Sigma) dissolved in 
water at a human bioequivalent dose of 40 mg/kg for 14 days and negative controls were treated 
with the drug candidate vehicle. Infected animals were randomly assigned into dose groups (n = 
4–6/group). Experimenters involved in dosing were blinded to treatment group. Necropsies were 
performed at 65-77 dpi using an overdose of isoflurane (Baxter) and adult worms were isolated 
from the thoracic cavity and peritoneum and were enumerated. Mice used for L. sigmodontis 
infection were housed at the animal facility of the Institute for Medical Microbiology, 
Immunology and Parasitology, University Hospital Bonn, Germany, at a 12 h light/dark cycle in 
  
individually ventilated cages with food and water ad libitum. The animal experiments were 
performed according to the European Union animal welfare guidelines and all protocols had 
been approved by the Landesamt für Natur, Umwelt und Verbraucherschutz, Cologne, Germany 
(AZ 84-02.04.2015.A507). Wolbachia depletion in L. sigmodontis female adult worms following 
compound treatment in vivo was determined as previously described (36, 64), where remaining 
intact female adult worms (up to ten per mouse) were individually assessed for Wolbachia ftsZ 
and L. sigmodontis actin values by qRT-PCR.  
SCID mouse in vivo anti-wolbachial efficacy models 
To determine compound efficacy against Wolbachia in O. ochengi and B. malayi, validated 
murine macrofilaricide drug screening infection models were used, as previously described (10, 
11). For the O. ochengi model, 12 adult O. ochengi males harvested from nodules of naturally 
infected cattle purchased from local herds near Ngaoundere, Adamawa Province, Cameroon 
were implanted intraperitoneally into CB.17 SCID mice (purchased from Charles River, UK) (n 
= 6/group). Treatment commenced 72 h post implant. Vehicle control was administered for 7 
days BID, doxycycline at 25 mg/kg BID was administered for 28 days, and CBR715 at 50 mg/kg 
BID was administered for 7 or 14 days. Sparse PK was taken during treatment, and at the end of 
the experiment (35 days after treatment was initiated) the adult worm burden, worm motility, and 
Wolbachia load via qPCR were determined. The washout periods were: 1 week for doxycycline 
control or 4 and 3 weeks CBR715, for 7- and 14-day treatments, respectively. For the B. malayi 
model, CB.17 SCID mice (n = 5/group) were inoculated with 75 B. malayi infectious L3 larvae 
obtained from female adult Aedes aegypti mosquitoes which were fed with B. malayi 
microfilariae collected from infected gerbils. Treatment commenced seven weeks post infection. 
Vehicle control was administered for 5 days BID, doxycycline at 25 mg/kg BID was 
administered for 42 days, and CBR715 at 50 mg/kg BID was administered for 7 or 14 days. At 
the end of the experiment (13 weeks post infection) the adult worm burden, microfilaria 
production, and Wolbachia load via qPCR were determined. No washout period existed for the 
doxycycline control, while washout period for CBR715 was 5 and 4 weeks, for 7- and 14-day 
treatments, respectively. 
  
  
L. loa microfilaria in vitro assay 
L. loa in vitro microfilaria motility drug assays were carried out as previously described (12) 
with the following amendments. L. loa microfilariae were obtained from splenectomised infected 
baboons (Papio anubis) infected with the L. loa human strain as previously described (13). The 
acquisition, care and ethical concerns on the use of baboons as donors of microfilariae have been 
previously described (13). Ethical and administrative clearances for the use of baboons in this 
study were obtained from the Ministry of Scientific Research and Innovation of Cameroon 
(Research permit #028/MINRESI/B00/C00/C10/C12) and the Animal Care Committee at 
REFOTDE. Procedures adhered to the NIH Guide for the Care and Use of Laboratory Animals. 
Purified L. loa were seeded at 30-50 microfilariae per well wells of 96-well plates pre-cultured 
with a monkey kidney cell line monolayer in DMEM + 10% FCS (LLC-MK2; a gift from Dr. 
Simon Townson, Northwick Park Institute for Medical Research). Drug compounds were 
prepared (blinded) at 100 mM in DMSO before being diluted and added to microfilaria cell 
cultures in triplicate using a six-point, 0.5 log-fold dilution series starting at 100 M in complete 
medium. The number of immotile (stretched, straight) and motile microfilariae were observed 
manually in each well using an inverted tissue culture microscope on day 5. Each microfilaria 
was monitored for a period of approximately 2 seconds to detect any motility. Stretched 
microfilariae would be more closely monitored for around 5 seconds to confirm no motility 
especially at anterior or posterior ends over that period before being scored as immotile. The 
percentage motile microfilariae per well were calculated. Hills Slope IC50 was fitted and 
calculated using GraphPad Prism v6.0. 
Permeability, metabolic stability, protein binding and solubility studies 
Studies were carried out at WuXi AppTec (Shanghai, China). For LC/MS/MS analysis, test and 
control compounds were quantified using peak area ratio of analyte and internal standard. Caco-2 
cell permeability assay was carried out using a standard protocol. Briefly, Caco-2 cells (ATCC) 
were seeded onto polyethylene membranes (PET) in 96-well BD Insert plates at 1 x 105 
cells/cm2, and medium was refreshed every 4–5 days until confluent cell monolayer formation 
(21–28 days post seed). Following addition of compounds, the plate was incubated for 2 h 
without shaking and compounds were tested at 2 μM bi-directionally in duplicate. 
Concentrations of test and control compounds in starting solution, donor solution, and receiver 
  
solution were quantified by LC/MS/MS. The metabolic stability in liver microsomes was 
determined using the compound depletion approach and quantified by LC/MS/MS. Human, 
mouse, rat, and dog microsomes were used (BD Gentest). The rate and extent of metabolism was 
determined by the disappearance of the parent compound, allowing for the determination of in 
vitro half-life (t1/2), intrinsic clearance (Clint) and the extraction ratio (ER) in various species. 
Protein binding to human and CD-1 mouse plasma was determined using equilibrium dialysis. 
Compounds were tested at 2 μM in triplicate, and concentrations were quantified by LC/MS/MS. 
Kinetic solubility in 50 mM phosphate buffer pH 6.8 was measured using the shake flask method 
followed by HPLC-DAD analysis. 
Cytochrome P450 analysis 
Quinazolines were subjected to cytochrome P450 inhibition analysis using five different 
isoforms using standard procedures (human liver microsomes, BD Gentest). Compounds were 
tested in a 7-point two-fold dilution series starting at 50 μM. Human PXR induction was 
evaluated by Puracyp Inc (Carlsbad, CA) in the DPX2 Luciferase cell-based in vitro assay (14) 
in a 6-point three-fold serial dilution starting at 30 μM. 
P-glycoprotein MDCK-MDR1 
MDR1-MDCK II cells (obtained from Piet Borst at the Netherlands Cancer Institute) were 
seeded onto polyethylene membranes (PET) in 96-well BD insert systems at 2.3 x 105 cells/cm2 
and grown until confluent cell monolayer formation (4–7 days). Cells were treated with 
compounds of interest and verapamil (positive inhibitor) in an 8-point three-fold serial dilution 
starting at 50 µM (100 µM for verapamil) together with digoxin at 10 µM, in duplicate. 
Permeation of digoxin from apical to basal direction or basal to apical direction was determined 
over a 150-minute incubation at 37°C and 5% CO2 with saturated humidity. Digoxin was 
quantified by LC/MS/MS analysis based on the peak area ratio of analyte and internal standard, 
and IC50 of the test compounds was calculated by SigmaPlot (V.11). 
Pharmacokinetic Studies 
Pharmacokinetic studies were conducted at GVK-Bio (India), Calibr (San Diego, CA), or WuXi 
(Shanghai, China) in accordance with IACUC guidelines. Male CD-1 fasted mice (three per 
  
group) were dosed per os (PO) or intravenously (IV) as indicated for each compound and 
formulation. Plasma concentration of each test article was monitored up to 72 h. 
hERG manual patch clamp assay 
Compounds were tested for effect on hERG potassium channels using the whole-cell patch 
clamp technique with a Multiclamp 700 patch-clamp amplifier (Molecular Devices, USA) at 
WuXi AppTec (Shanghai, China). CHO cells stably expressing hERG potassium channels from 
Aviva Biosciences (San Diego, CA) were tested with compounds at five concentrations, in a 
three-fold serial dilution starting at 30 μM, and compared to vehicle (negative) control and 
Amitriptyline (WuXi AppTec, Shanghai, China) (positive) controls. Percentage of control 
(vehicle) values were calculated in duplicate for each concentration of drug, and data analysis 
were performed using Clampfit (V10.7, Molecular Deveices) and GraphPad Prism 5.0. 
Mini-Ames 
The ability of CBR417 and CBR490 to induce reverse mutations both in the presence and 
absence of S9 mix at the histidine locus in the genome of four strains of Salmonella typhimurium 
(TA98, TA100, TA1535, and TA1537) and at the tryptophan locus in the genome of Escherichia 
coli WP2 uvrA (pKM101) was determined at WuXi AppTec (Shanghai, China). The tested dose 
levels in the mutagenicity assay with five tester strains in the presence and absence of S9 mix 
were 1.5, 4, 10, 25, 64, 160, 400, and 1000 µg per well, three wells per dose.  
In vitro micronucleus induction 
In vitro microwell micronucleus screening assay in Chinese hamster ovary cells (CHO-WBL, 
Merck Research Laboratories, USA) was carried out at WuXi AppTec (Shanghai, China). 
Clastogenicity/aneugenicity was measured by the extent of micronucleus formation with and 
without exogenous metabolic activation (Aroclor 1254 induced rat liver S9, Molecular 
Toxicology (Boone, NC)). Cultures of CHO-WBL cells in Microwell 8-well chamber slides 
(Thermo Fisher Scientific Inc.) were exposed in duplicates to 18 concentrations of CBR417 or 
CBR490 (444.38 μg/mL top concentration) as well as to positive (Cyclophosphamide 
monohydrate, Mitomycin C) and solvent controls. In the S9 activated test system, exposure was 
for 3 h; in the non-activated test system, treatment was for 3 h and for 24 h. Cells were fixed, 
  
stained with acridine orange, and 2000 binucleated cells (1000 binucleated cells/well) were 
scored for each test and control article concentration. 
In vitro safety profiling assays 
The Eurofins SafetyScreen44TM Panel (Cerep) and the Cardiac Profiler safety panels were used 
to assess the off-target effects of CBR417 and CBR490 at a single concentration of 10 μM. The 
SafetyScreen44 includes binding and enzymatic inhibition assays performed on targets that have 
been found associated with adverse drug reactions in vivo (15) and the Cardiac Profiler panel 
assesses inhibition of eight key cardiac channels in functional cell-based assays.  
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Supplementary Fig. 1. Classes of known drugs and bioactive molecules identified as potent 
and selective anti-wolbachial hits in the primary in vitro screen. Duplicates (e.g. retapamulin 
and ketoconazole, which were identified in both the ReFRAME and Bioactive libraries) were 
counted only once in this analysis.  
 
 
 
  
  
 
Supplementary Fig. 2. Wolbachia distribution in ovaries and the hypodermis of DMSO-
treated worms. Adult female B. pahangi worms were treated ex vivo with 0.1% DMSO vehicle 
control for three days. Worms were fixed and ovaries were dissected away from the body wall 
sections of the worm. Fragments of each tissue were stained with DAPI (green) and Wolbachia-
specific 16S rRNA FISH (white or magenta) and imaged using a confocal microscope. A 
composite image of a single worm ovary stained with DAPI (A) and 16S rRNA FISH (B) 
acquired using a 10x objective is shown. Insets show the distal ovary section (area outlined with 
a yellow box) acquired using a 63x objective. Oviduct, largely devoid of Wolbachia is indicated. 
DTC, distal tip cell. Variable Wolbachia distribution in representative sections of the hypodermis 
imaged using a 10x (C) or 63x (D) objective are shown. Magnified areas shown in D are outlined 
in C with yellow boxes. Scale bars (white) = 100 m. Scale bars (cyan) = 10 m. 
  
 
 
  
Supplementary Fig. 3. Wolbachia elimination from B. malayi worm ovaries ex vivo. As in 
the secondary validation screen, B. pahangi and B. malayi adult female worms were maintained 
ex vivo in the presence of compounds of interest. After three days, the worms were frozen, fixed, 
and dissected to isolate the ovaries. The ovaries were stained for Wolbachia 16S rRNA and total 
DNA, and their distal tips imaged using a confocal microscope with a 63x objective. The images 
were analyzed for the specific Wolbachia signal using HCI analysis software. Two worms 
(yielding a maximum of four ovaries) were included in each treatment except for the DMSO 
treatment where four worms were included. A) Representative images from neutral control 
(DMSO-treated), positive control (1 M doxycycline-treated), 1 M CBR422, 1 M tylosin, and 
1 M mCEB6625-treated B. malayi ovaries stained with DAPI (green) and Wolbachia 
(magenta). DTC, the distal tip cell, is indicated with a dashed outline. Scale bar = 10 m. B) 
Compound activity against wBm within B. malayi ovaries treated ex vivo. Data from one 
experiment are plotted as mean  stdev. C) Compound activity against wBp within B. pahangi 
ovaries treated ex vivo determined at the same time as for B. malayi. Data from one experiment 
are plotted as mean  stdev. D) EC50 values estimated from data in B and C. 
 
  
  
 
Supplementary Fig. 4. Sparse pharmacokinetic profiles of quinazoline anti-wolbachials 
during efficacy studies. Limited exposures were determined during rodent models of filarial 
infection. Sparse pharmacokinetic profiles for efficacy studies performed in the L. sigmodontis 
mouse model of infection. Formulations and BID doses are as in figure 6B. PFD, post first dose; 
PLT, post last dose; P3rdD, post third dose; PLmD, post last morning dose.  
 
 
  
 
Supplementary Fig. 5. Wolbachia elimination following quinazoline treatment in the 
mouse/L. sigmodontis in vivo model of filarial infection. Data, for which median % Wolbachia 
elimination is reported in Table 2 of main text is shown here. Wolbachia quantities per worm are 
determined by the ratio of Wolbachia ftsZ gene to that of filarial actin. Vehicle control (black 
puncta and dashed lines for median values) and a 14-day 40 mg/kg BID doxycycline control 
(blue puncta and dashed lines for median values) is included for each experiment (A–D). Note 
that data in (B) are from the same experiment as shown in figure 6B testing efficacy of CBR715, 
and data in (D) are from the same experiment as shown in figure 6B testing efficacy of CBR417 
and CBR490. These shared controls with data reported in main figure. Medians with 95% CI are 
shown (nd, no significant difference; * P-value < 0.05; ** P-value < 0.01; **** P-value < 
0.0001). DOX, doxycycline; mpk, mg/kg. 
  
 
 
 
 
 
 
 
Supplementary Fig. 6. CBR417 and CBR490 dose-response relationship based on 
Wolbachia elimination in mouse/L. sigmodontis efficacy studies. Efficacy, expressed as Log 
(1+ % change from vehicle control in Wolbachia levels), was plotted against dose (mg/kg) and 
total dose (mg/kg/day) for CBR490 (A, B) and CBR417 (C, D). An exponential one-phase decay 
analysis was applied to generate the dose-response relationship models, however sufficient data 
was unavailable to generate unambiguous curves for CBR417 studies. 
 
 
 
  
  
 
Library Bioactives Diversity I Diversity II Diversity III ReFRAME 
Total 
(primary screen format) (384w) (1536w) (384w) (1536w) (1536w) 
Compounds screened [2.5 µMa] 10,673 86,844 94,697 95,337 12817 300,368 
Primary hitsb 324 424 807 199 360 2,114 
Average Z’ 0.6253 0.5224 0.539 0.4058 0.5730 0.5331 
Hit rate 3.04% 0.50% 0.85% 0.21% 2.81% 0.70% 
Reconfirmation rate 79.3% 
(straight 
into DR) 
48.3% 33.2% 
(straight    
into DR) 
  
Tested in dose response (DR) 214 448 390 78 357 1,487 
IC50 < 1 µM 
133  
(< 1.1 µM) 
143 
171  
(< 1.1 µM) 
43  
(60 IC50 < 2 µM) 
194 684 
IC50 < 1 µM, CC50:IC50 > 10 60 128 162 
30  
(39 IC50 < 2 µM) 
101 481 
Tested as powders 46c 116 161 36 n/a 313 
Powders reconfirmed (1536w) 
IC50 < 1 μM 
38 35 115 30 n/a 218 
Powder reconfirmation rate 83% 30% 71% 83% n/a 70% 
Potent and selective (IC50 <     
1 µM, CC50:IC50 > 10) 
33 24 108 30 n/a 296 
Filtered for ex vivo validation 
screend 
20 21 53 9 34 137 
Validated (> 75% wBp 
elimination in ovaries) 
2 4 19 3 4 32 
Validation rate 10.0% 19.0% 35.8% 33.3% 11.8% 23.4% 
Hits of interest PQ 401   
quinazolines: 
CBR008 
  
tylosin 
ketoconazole 
  
              
a A fraction of Diversity III library was screened at 1.25 µM.  
b Primary hit thresholds: Bioactives, Diversity II, Diversity III, and ReFRAME: ≥ 60 % inhibition.  Diversity I: ≥ 70% inhibit ion. 
c 14 compounds were omitted due to overt toxicity in mammalian cells (ten compounds had CC50s < 1 μM) or duplication (2x 
doxycycline and 2x novobiocin were removed) 
d Hits filtered for validation based on activity and structure relationships. 
n/a: not applicable 
Table S1. Primary and validation screen statistics. 
  
 
  IC50 (μM) 
  CBR417 CBR490 
Acinetobacter baumannii > 40 > 40 
Bacillus subtilis > 40 > 40 
Enterococcus faecalis > 40 > 40 
Enterococcus faecium > 40 > 40 
Escherichia coli > 40 > 40 
Klebsiella pneumoniae > 40 > 40 
Pseudomonas aeruginosa > 40 > 40 
Staphylococcus aureus 10.67 > 40 
 
Table S4. Activity of optimized anti-wolbachial leads against a panel of gram-positive and 
gram-negative bacteria. 
 
 
 
 
  
  
 
  Screen Hit 
Failed 
Subseries 
Lead 
Successful 
Subseries 
Lead 
Advanced Leads 
  CBR008 CBR063 CBR422 CBR625 CBR715 
subseries amide amide oxadiazole oxadiazole methylpyridine 
Kinetic Solubility (M) 1 1 1 2.76 1.11 
Melting Point (C) n/d n/d n/d 155 – 157 243 
cLogP 5.68 6.1 4.68 3.94 5.88 
LipE 0.85 0.95 3.48 4.30 1.81 
Plasma Protein Binding 
99.43 % 
(mouse) 
99.72 % 
(mouse) 
99.345 % 
(mouse) 
99.51 % 
(mouse) 
99.98 % 
(human) 
98.53 % 
(mouse) 
Metabolic stability           
CLint (L/min/mg) (Mouse) 438.03 129.36 13.379 70.3 67.2 
CLint (L/min/mg) (Human) n/d n/d 27.51 39.06 34.339 
CLint (L/min/mg) (Dog) n/d n/d n/d 9.6 28.52 
CLint (L/min/mg) (Rat) n/d n/d n/d 9.6 30.505 
ER (Mouse) 0.95 0.85 0.37 0.756 0.747 
ER (Human) n/d n/d 0.5446 0.629 0.599 
ER (Rat) n/d n/d n/d 0.2 0.499 
ER (Dog) n/d n/d n/d 0.3 0.571 
Cytochrome P-450 isoform 
inhibition (IC50) (μM) 
          
CYP 1A2 n/d 3.00 0.33 5.14 1.09 
CYP 2C19 n/d > 50 7.51 8.61 23.26 
CYP 2C9 n/d > 50 7.11 17.81 17.86 
CYP 2D6 n/d > 50 27.73 32.77 > 50 
CYP 3A4 n/d > 50 9.68 > 50 > 50 
hERG inhibition 
(cardiotoxicity) 
          
% inhibition at 5 μM n/d 6.59 n/d 46.24 9.6 
IC50 (μM) n/d n/d 11.81 5.03 n/d 
Permeability Caco-2           
Papp A-B (10-6 cm/s) n/d 0.047 2.98 n/d 0.41 
Papp B-A (10-6 cm/s) n/d 0.086 2.62 n/d 0.96 
Stability determined in microsomes. CLint, intrincic clearance; ER, extraction ratio. Papp, permeability, determined in Caco-2 cells. 
Table S6. ADME properties of quinazoline anti-wolbachials. 
  
 
Supplementary tables provided as Excel files: 
Table S2. Anti-wolbachial activities of known drugs and bioactive molecules identified as potent 
and selective hits in the primary in vitro screen (powders and ReFRAME compounds). 
Table S3. Antibacterial activities of primary screen hits from Bioactive, Diversity I and 
Diversity II libraries.  
Table S5. Activities of screening hits validated ex vivo (all except ReFRAME compounds are 
powders). 
Table S7. Pharmacokinetic properties of anti-wolbachial quinazolines. 
Table S8. Cardiac Panel Study Results for CBR417 and CBR490. 
Table S9. Safety Pharmacology Profiling Study Results for CBR417 and CBR490.  
Data file S1. Primary data. 
 
 
 
